secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001193805-26-000516
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic appoints Michael Panzara as CMO; prior CMO Andreas Muehler resigns, transitions to consultant
--------------------------------------------------------------------------------

- Michael Panzara appointed CMO effective April 24, 2026; base salary $600K, annual bonus target ≥50% of salary, signing bonus $125K.
- Andreas Muehler resigned as CMO effective April 27, 2026; will serve as Senior Medical Officer through April 30, then consultant 10 months at $10K/month.
- Panzara granted inducement option for 300K shares (post-split) vesting 50% at 1 year, 50% over 24 months thereafter.
- Muehler receives 12 months base salary severance, pro-rated FY2026 bonus, full equity vesting, and 3-year post-termination exercise window.
- No disagreement cited for Muehler's departure; Panzara brings >25 years neurology drug development experience including MS approvals at Biogen/Sanofi.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526000516/0001193805-26-000516-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526000516/e665394_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-26-000516

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer